This year in the United States and Europe, over 30,000 patients will receive a hematopoietic stem cell transplantation (HSCT). Of these, over 10,000 will experience a severe viral infection post-transplant.

Our mission is to safely and effectively treat viral infections that attack people with weakened immune systems.

ViraCyte™ Science

ViraCyte™ products include: Viralym: “ready to administer” T cell products to treat patients with active infection Prelym: a personalized product prepared from the HSCT donor that can be used to prevent viral infections

Together, Viralym and Prelym comprise a full spectrum of solutions to eliminate infections after HSCT.

ViraCyte™ Pipeline